Table 1.
Differences in clinical and laboratory characteristics at admission among patients receiving HD vs. patients receiving LD of intravenous furosemide
| HD (n = 71) | LD (n = 50) | p-Value | |
|---|---|---|---|
| Age (years) | 82 (77–87) | 79 (76–85) | 0.13 |
| Gender (n) | |||
| Male | 30 | 21 | 0.98 |
| Female | 41 | 29 | (Ref) |
| Laboratory data at admission | |||
| Creatinine (mg/dL) | 1.70 (1.20–2.10) | 1.35 [1.17–1.59) | 0.005 |
| eGFR (ml/min/1.73 m2) | 41 (32–51) | 46 [38–58) | 0.04 |
| BUN (mg/dL) | 85 (59–112) | 66 [42–106) | 0.04 |
| Serum sodium (mEq/L) | 138 (130–142) | 140 [138–143) | 0.007 |
| Serum potassium (mEq/L) | 4.2 (4.0–4.5) | 4.0 (3.7–4.5) | 0.02 |
| BNP (pg/mL) | 887 (563–1350) | 837 (530–1275) | 0.68 |
| LVEF (%) | 30 (25–35) | 40 (35–40) | <0.001 |
| Admission congestion score >2 (%) | 63 | 36 | 0.003 |
| Risk Factors (%) | |||
| Diabetes | 51 | 22 | 0.001 |
| Dyslipidemia | 49 | 44 | 0.57 |
| Hypertension | 48 | 44 | 0.67 |
| CAD | 69 | 54 | 0.09 |
| CKD | 61 | 28 | <0.001 |
| AF | 39 | 30 | 0.29 |
| Background therapy (%) | |||
| Loop diuretics | 100 | 96 | 0.33 |
| ACE/ARBs | 59 | 64 | 0.73 |
| Beta blockers | 72 | 76 | 0.76 |
| Aldosterone antagonists | 24 | 22 | 0.98 |
Abbreviations: atrial fibrillation (AF); B-type natriuretic peptide (BNP); blood urea nitrogen (BUN); chronic kidney disease (CKD); coronary artery disease (CAD); estimated glomerular filtration rate (eGFR); high dose (HD); left ventricular ejection fraction (LVEF); low dose (LD).